Pheno Therapeutics in-licenses small molecules from UCB Pharma

British biotech Pheno Therapeutics has announced a licensing deal with Belgium’s largest drugmaker UCB (Euronext: UCB), focusing on the science of remyelination.

Pheno, a start-up based in Edinburgh, is working on the discovery and development of small molecules that use this mechanism of action to treat neurological diseases such as multiple sclerosis (MS).

The exclusive worldwide license agreement with UCB will give the firm access to a pre-clinical-stage program of novel small molecules which promote remyelination, a phenomenon whereby new myelin sheaths are generated in the central nervous system.